Phase 1 data for divarasib in lung and colorectal cancers look good versus Lumakras and Krazati’s earlier showings.

A statistical analysis of Skyscraper-01’s second interim read is inadvertently posted on a Roche website.

With sales of the Amgen KRAS inhibitor flatlining an advisory panel is called to discuss its continued US approval.

However, the design of the Contact-02 study, and the relevance of the positive PFS endpoint, will be debated.

PD-(L)1 players are increasingly looking to subcutaneous delivery to maintain market share, and next month brings a major catalyst.

Flaura2 takes centre stage, while Trodelvy and dato square off in PD-1 combo trials.